Soft tissue sarcoma (STS) · None

Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.

Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.

Source YAML: complete record

Track	standard
Linked regimen	`None`

ID	`IND-WERNER-CARRIER-SURVEILLANCE`
Type	Indication
Status	reviewed 2026-05-20 \| pending_clinical_signoff
Diseases	`DIS-SOFT-TISSUE-SARCOMA`
Sources	`SRC-NCCN-CNS-2025` `SRC-NCCN-MELANOMA-2025` `SRC-NCCN-STS-2025` `SRC-NCCN-THYROID-2025`

Notes

STUB — Wave O confirmed-carrier surveillance pathway (Werner / WRN). Two-Clinical-Co-Lead signoff queued per CHARTER §6.1 dev-mode. Sibling — IND-WERNER-CARRIER-INTENSIFIED (aggressive plan_track).

Used By

Indication

IND-WERNER-CARRIER-INTENSIFIED - IND-WERNER-CARRIER-INTENSIFIED

Red flag

RF-WERNER-CONFIRMED-CARRIER - Confirmed biallelic germline pathogenic / likely-pathogenic variants in WRN (RECQL2; Wern...